Natixis Apellis Pharmaceuticals, Inc. Transaction History

Natixis

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$55.39 - $72.47 $5.02 Million - $6.57 Million	-90,719 Reduced 98.55%	1,339 $78,000
Q4 2023 Feb 13, 2024	BUY	$37.14 - $64.82 $3.1 Million - $5.42 Million	83,558 Added 983.04%	92,058 $5.51 Million
Q3 2023 Nov 14, 2023	BUY	$23.65 - $89.22 $201,025 - $758,370	8,500 New	8,500 $323,000
Q1 2023 May 12, 2023	SELL	$46.59 - $66.96 $15.3 Million - $22 Million	-329,300 Reduced 95.45%	15,700 $1.04 Million
Q4 2022 Feb 24, 2023	BUY	$43.24 - $61.04 $4.41 Million - $6.23 Million	102,000 Added 41.98%	345,000 $17.8 Million
Q4 2022 Feb 13, 2023	SELL	$43.24 - $61.04 $1.69 Million - $2.38 Million	-39,000 Reduced 13.83%	243,000 $12.6 Million
Q3 2022 Nov 14, 2022	SELL	$44.76 - $69.66 $1.43 Million - $2.23 Million	-32,000 Reduced 10.19%	282,000 $19.3 Million
Q2 2022 Aug 12, 2022	BUY	$35.07 - $59.21 $1.61 Million - $2.72 Million	45,900 Added 17.12%	314,000 $14.2 Million
Q1 2022 May 13, 2022	BUY	$35.46 - $54.12 $9.51 Million - $14.5 Million	268,100 New	268,100 $13.6 Million
Q4 2021 Feb 14, 2022	SELL	$30.74 - $49.16 $6.66 Million - $10.6 Million	-216,500 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$31.4 - $69.84 $3.37 Million - $7.49 Million	107,300 Added 98.26%	216,500 $7.14 Million
Q2 2021 Aug 13, 2021	BUY	$40.9 - $64.9 $4.47 Million - $7.09 Million	109,200 New	109,200 $6.9 Million

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.